Atara Biotherapeu…
USUSDAtara Biotherapeutics Inc (LSE:0HIY) — Biotechnology: Biological Products (No Diagnostic Substances). Biržų, kuriose prekiaujama bendrovės akcijomis, skaičius: 2. Šiame puslapyje — kaina ir grafikas, dividendai, didžiausi akcininkai ir akcijų skaičiaus istorija.
Apie Įmonę
- Svetainė
- atarabio.com
- Investuotojams
- investors.atarabio.com/news-events/press-releases
- Sektorius
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Būstinė
- South San Francisco, United States
- Generalinis Direktorius
- Anhco Nguyen
- Darbuotojai
- 10
- Įkurta
- 2012
- Biržoje Nuo
- 29.01.2018 (LSE:0HIY)
- Apyvartoje Esančios Akcijos
- 10.04 mln. 2026-08-10 duomenimis
- Laisvai Apyvartinės Akcijos
- 4.62 mln.
- Rinkos Kapitalizacija
- 95.16 mln. USD
- Insaideriai
- 16.8%
- Instituciniai Investuotojai
- 57.67%
- Šaka (SIC)
- Biological Products, (No Diagnostic Substances)
- LEI
- 549300WBXUXZRE03MS38
- P/E
- nuostolis
- FCF
- −50.9 mln. USD
- Skola
- ?
- Pelnas ir FCF – už 12 mėnesių iki 30.06.2026 (naujausia įmonės ataskaita).
Aprašymas
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Didžiausi Akcininkai
| Turėtojas | Dalis | Akcijos | Ataskaitos Data |
|---|---|---|---|
| EcoR1 Capital, LLC | 15.46% | 1.55 mln. | 2026-06-30 |
| CIONGOLI GREGORY AUSTIN… | ≈12.17% | 1.22 mln. | 2026-06-09 |
| Adage Capital Partners G… | 8.47% | 850 000 | 2026-06-30 |
| Point72 Asset Management… | 6.85% | 687 718 | 2026-06-30 |
| Redmile Group, LLC | 4.4% | 441 701 | 2026-06-30 |
| Vanguard Capital Managem… | 2.46% | 247 047 | 2026-06-30 |
| Mackenzie Financial Corp… | 2.32% | 233 249 | 2026-06-30 |
| CHERRY BRIAN N (Director… | ≈1.66% | 166 486 | 2026-09-04 |
| VANGUARD INDEX FUNDS-Van… | 1.58% | 158 646 | 2026-06-30 |
| NGUYEN ANHCO T (Chief Ex… | ≈1.32% | 132 775 | 2026-08-17 |
| Blackrock Inc. | 0.84% | 84 455 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.82% | 82 758 | 2026-06-30 |
| TOUCHON PASCAL (Director… | ≈0.78% | 77 955 | 2025-06-10 |
| Geode Capital Management… | 0.75% | 75 128 | 2026-06-30 |
| HYLLENGREN ERIC J (Chief… | ≈0.56% | 56 231 | 2025-03-03 |
| Staley Capital Advisers,… | 0.5% | 50 000 | 2026-06-30 |
| Vanguard Fiduciary Trust… | 0.43% | 43 036 | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 35 392 | 2026-07-31 |
| iShares Trust-iShares Mi… | 0.19% | 18 824 | 2026-08-31 |
| Varbl Insurance Prod. Fd… | 0.16% | 16 238 | 2026-07-31 |
| Fidelity Concord Street… | 0.11% | 11 175 | 2026-07-31 |
| Fidelity Concord Street… | 0.1% | 10 479 | 2026-07-31 |
| Fidelity Concord Street… | 0.05% | 4 612 | 2026-07-31 |
| VANGUARD Inst. INDEX Fd.… | 0.03% | 2 844 | 2026-06-30 |
| VANGUARD VALLEY FORGE FU… | 0.03% | 2 799 | 2026-06-30 |
| ADIUMENTUM CAPITAL FUND… | — | — | 2025-05-16 |
| ECOR1 CAPITAL, L.L.C. (B… | — | — | 2026-05-07 |
| PANACEA INNOVATION LTD (… | — | — | 2026-05-07 |
| PANACEA VENTURE (Benefic… | — | — | 2025-11-28 |
| REDMILE GROUP, L.L.C. (U… | — | — | 2026-07-22 |
Prisijunkite su Google